Elevated VAFs, particularly for JAK2 V617F, are linked to increased hematologic abnormalities and thrombotic risk in PV and ET patients, whereas CALR mutations correlate with distinct disease manifestations and outcomes. The gene discussed is CALR; the disease is acquired polycythemia vera.